Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab (BI 655130) in perianal fistulizing Crohn's disease
NCT03752970Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2019
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of spesolimab in Crohn's disease, sponsored by Boehringer Ingelheim. Started Feb 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03752970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752970.